Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amyris (AMRS) stocks in Canada

Learn how to easily invest in Amyris stocks.

Amyris (AMRS) is a leading specialty chemicals business based in the US. It opened the day at $15.65 after a previous close of $15.44. During the day the price has varied from a low of $15.07 to a high of $15.76. The latest price was $15.67 (25 minute delay). Amyris is listed on the NASDAQ and employs 595 staff. All prices are listed in US Dollars.

How to buy shares in Amyris

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amyris stock price (NASDAQ:AMRS)

Use our graph to track the performance of AMRS stocks over time.

Amyris shares at a glance

Information last updated 2021-07-09.
Previous close$15.44
Change $0.23
Change % 1.4896%
Volume 1,146,366
Information last updated 2022-01-17.
52-week range$4.34 - $23.42
50-day moving average $6.47
200-day moving average $12.42
Wall St. target price$19.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.51

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Amyris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Amyris price performance over time

Historical closes compared with the close of $15.67 from 2022-01-21

1 week (2022-01-13) 214.03%
1 month (2021-12-23) 180.32%
3 months (2021-10-22) 11.69%
6 months (2021-07-23) 0.71%
1 year (2021-01-22) 50.82%
2 years (2020-01-24) 451.76%
3 years (2019-01-24) 370.57%
5 years (2017-01-24) 2,419.29%

Is Amyris under- or over-valued?

Valuing Amyris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amyris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amyris's EBITDA

Amyris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.1 million.

The EBITDA is a measure of a Amyris's overall financial performance and is widely used to measure a its profitability.

Amyris financials

Revenue TTM $356.8 million
Gross profit TTM $14.8 million
Return on assets TTM -8.6%
Return on equity TTM 0%
Profit margin -117.28%
Book value $-1.79
Market capitalisation $1.5 billion

TTM: trailing 12 months

Amyris share dividends

We're not expecting Amyris to pay a dividend over the next 12 months.

Have Amyris's shares ever split?

Amyris's shares were split on a 1:15 basis on 6 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amyris shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Amyris shares which in turn could have impacted Amyris's share price.

Amyris share price volatility

Over the last 12 months, Amyris's shares have ranged in value from as little as $4.34 up to $23.42. A popular way to gauge a stock's volatility is its "beta".

AMRS.US volatility(beta: 1.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amyris's is 1.5246. This would suggest that Amyris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Amyris overview

Amyris, Inc. , a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site